Gareth J. Sanger (born 1953) is a British pharmacologist.
Gareth Sanger | |
|---|---|
| Nationality | United Kingdom |
| Employers | |
| Website | www |
Sanger was a research fellow at King's College Hospital Medical School from 1977 to 1990.[1] He then spent a period in the pharmacological industry,[1] before being appointed, in 2009, Professor of Neuropharmacology, at Queen Mary University of London.[2]
He has served as editor and reviews editor for the "British Journal of Pharmacology" and as an editorial board member for "Drug Discovery Today".[1]
Together with M Tyers he received the 1998 Pharmaceutical Research and Manufacturers of America (PhRMA) "Discoverer's Award" for their research into 5HT3 receptor/antiemesis, which led to the identification and development of the drug Kytril,[1][2] an antiemetic to treat nausea and vomiting following chemotherapy.
References
edit- ^ a b c d Daphne Christie; Tilli Tansey, eds. (2007). The Discovery, Use and Impact of Platinum Salts as Chemotherapy Agents for Cancer. Wellcome Witnesses to Contemporary Medicine. History of Modern Biomedicine Research Group. ISBN 978-0-85484-112-7. OL 25554713M. Wikidata Q29581749.
- ^ a b "Gareth Sanger". The Conversation. Retrieved 26 June 2017.